Nutritional science, healthy aging research, and NAD+ innovation by Niagen

Niagen Bioscience CEO Rob Fried is set to present at the East Coast IDEAS Investor Conference on Thursday, June 11, from 2:40 to 3:15 PM Eastern Time at The Westin Times Square in New York, NY. ...

Niagen Bioscience draws attention to the nuanced challenges in the study of NAD biology and biomarker research. The company shared insights from Charles M. Brenner, a leading figure in the NAD ...

Niagen Bioscience announced that its Chief Financial Officer, Ozan Pamir, will participate in the 31st Annual Sohn Conference on May 12. Attendees are invited to arrange one on one meetings with ...

Niagen Bioscience has introduced a clinician-directed telehealth platform under its Niagen Plus service, giving eligible patients in the U.S. the ability to access prescription-only, ...

Niagen Bioscience has spotlighted the expertise of its Chief Scientific Advisor, Dr. Charles Brenner, in a recent interview with Live Foreverish, focusing on the science behind NAD and ...

Niagen Bioscience is attracting increased attention as the Los Angeles Times examines the potential of nicotinamide riboside (NR), a compound touted for its role in cellular energy and repair. ...

Niagen Bioscience, recognized for its leadership in NAD+ precursor technology, appears on the cover of Business by LA Times Studios for April 2026. The company reports over 40 published studies, ...

Niagen Bioscience has achieved a key milestone by securing the first ever U.S. Pharmacopeia (USP) monograph for its patented form of nicotinamide riboside chloride (NRCl). The company partnered ...

Niagen Bioscience announced that its patented form of nicotinamide riboside, Nicotinamide Riboside Chloride (NRCl), now officially has a published United States Pharmacopeia dietary supplement ...

Niagen Bioscience received an endorsement from leading scientists, as both Stanford professor Andrew Huberman and biomedical scientist Rhonda Patrick confirmed their personal use of Tru Niagen. ...

ChromaDex Corp. has been named the headline sponsor of the inaugural ‘NAD for Health: Opportunities & Challenges’ conference. The event, hosted by the University of Copenhagen from March 23 to ...

ChromaDex Corp. announced that Niagen Bioscience has released its financial results for the fourth quarter and fiscal year 2025. Investors and stakeholders are encouraged to visit the company’s ...

ChromaDex Corp. has completed the sale of its ChromaDex Reference Standards business to LGC in a move aimed at simplifying its operational structure. Rob Fried, chief executive officer of Niagen ...

Niagen Bioscience has broadened its intellectual property portfolio with the issuance of U.S. Patent No. 12,558,367, according to ChromaDex Corp. The newly granted patent covers innovations ...

ChromaDex Corp is diving deeper into the science of aging with a focus on new advancements and promising avenues. Rob Fried, the company's CEO, addressed these topics at Stanford's Consumer ...